




Xience V/Promus

The FDA recently approved the Xience V (Abbott Vascular, Santa Clara, CA) and the Promus (Boston Scientific Corporation, Natick, MA) Everolimus-Eluting Coronary Stent Systems for the treatment of coronary artery disease. The Promus stent is a private-labeled Xience V stent system designed and manufactured by Abbott Vascular and distributed by Boston Scientific under an agreement executed before the 2006 acquisition of the former Guidant Corporation by Boston Scientific. The Promus stent and the Xience V stent are identical products sold by the respective companies under the different brand names.

According to the companies, the stent is a next-generation drug-eluting stent that offers both ease of use and excellent clinical performance. Together, the Xience V and the Promus stents represent the only drug-eluting stent platforms to have demonstrated superiority over the market-leading drug-eluting stent in two randomized head-to-head clinical trials. Furthermore, at 2 years, Xience V showed a 45% reduction in the risk of major adverse cardiac events compared to the market-leading stent in the SPIRIT III clinical trial.

Dr. Gregg W. Stone of Columbia University Medical Center and chairman of the Cardiovascular Research Foundation stated, "Xience V was designed to improve safety and efficacy compared to earlier-generation stents. The long-term clinical data from two studies performed in both the US and Europe have now confirmed that Xience V is a

| | | |
|--|-----------------|-------------------------------|
| COMPANY | Abbott Vascular | Boston Scientific Corporation |
| PRODUCT | Xience V | Promus |
| PHONE | (800) 354-4094 | (763) 494-1700 |
| WEB | www.xiencev.com | www.bostonscientific.com |
| KEY FEATURES | | |
| <ul style="list-style-type: none"> • Thinnest drug-eluting stent platform available • Controlled release, low-dose everolimus • Biocompatible fluorinated copolymer | | |



true next-generation drug-eluting stent with clinically important benefits for patients."

"The Promus stent has shown outstanding deliverability, low late loss, and the potential to reduce the need for re-interventions," said Ted Feldman, MD, FSCAI, Director of the Cardiac Catheterization Laboratory at Evanston Northwestern Healthcare in Evanston, Illinois. "These benefits will make the Promus stent an attractive new treatment option for US physicians and their patients."

PressureWire Certus

| | |
|---|---------------------------|
| COMPANY | Radi Medical Systems Inc. |
| PHONE | (877) 337-7234 |
| WEB | www.radi.se |
| KEY FEATURES | |
| <ul style="list-style-type: none"> • Large entry funnel for fast and easy wire reconnection • Greatly reduced insertion friction • Easy to use on/off locking cap • Ergonomical design for improved wire handling | |



Radi Medical Systems (Wilmington, MA) recently announced improvements to their latest-generation pressure-sensing guidewire, which will begin shipments immediately. The PressureWire Certus is used in the assessment of fractional flow reserve (FFR). According to the company, the device features a new ergonomically designed proximal connector that provides three key advantages for physicians. The new large entry funnel allows for fast and easy wire reconnection into the proximal connector while also exhibiting less insertion friction. In addition, the new locking cap provides positive reinforcement when the wire and the connector are locked in place via a user-intuitive on- and off-twist function.

Nico Pijls, MD, from the Department of Cardiology at Catharina Hospital, Eindhoven, the Netherlands, commented, "I am pleased that improvements to PressureWire Certus occur frequently to assist in measuring FFR in more challenging anatomy, such as we faced in the recently completed FAME study. In this multicenter randomized trial involving 1,000 patients, FFR was measured in three arteries per patient using PressureWire. Successful, unequivocally interpretable measurement could be achieved in 99.3% of all coronary arteries thanks to recent improvements to the PressureWire." ■



GTX Coronary Stent System

| | |
|--|--|
| COMPANY | Global Therapeutics (Cook Medical's Cardiology Unit) |
| PHONE | (800) 457-4500 |
| WEB | www.cookmedical.com |
| KEY FEATURES <ul style="list-style-type: none"> • Eliminates technical challenges such as recoil, stent balloon retention, and stent spring-back. • Offers significant cost savings | |


Global Therapeutics, the cardiology unit of Cook Medical (Bloomington, IN), recently received CE Mark approval for the GTX Coronary Stent System, a cobalt chromium bare-metal coronary stent designed to fill the demand among interventional cardiologists for non-drug-eluting coronary stents. The GTX stent has been engineered specifically to eliminate the technical challenges associated with earlier cobalt chromium stent designs on the market, such as recoil, stent balloon retention, and stent springback. Because bare-metal stents historically cost about one-third as much as their drug-coated iterations, the GTX may offer significant cost savings during a time of skyrocketing health care costs for heart disease, the company says. Available currently in the European Union and United Kingdom, the GTX stent eliminates the concern of potential delayed reactions and late-stage thrombosis associated with drug-eluting coronary stents. According to the company, the GTX Coronary Stent System offers a significant advance in bare-metal stent technology and shows Cook Medical's ongoing commitment to cardiologists and hospitals by improving clinical outcomes and providing cost-effective alternatives.



Scoreflex Coronary Dilatation Catheter

| | |
|--|--------------------|
| COMPANY | OrbusNeich |
| PHONE | +31 33 254 1150 |
| WEB | www.orbusneich.com |
| KEY FEATURES <ul style="list-style-type: none"> • Designed for use in focused-force angioplasty • Dual-wire system creates a focal stress pattern to facilitate effective controlled plaque fracture at low-resolution pressure • Low crossing profile and unbeatable trackability | |

OrbusNeich (Hong Kong) recently received CE Mark approval for the Scoreflex Coronary Dilatation Catheter, which is designed for use in focused-force angioplasty, a technique in which the force resulting from balloon inflation in a stenotic lesion is concentrated at one or more locations within the stenosis. According to the company, published research has shown that focused-force angioplasty is effective in resolving resistant stenosis while reducing the frequency of complications with its use of gradual, low-pressure inflations. The Scoreflex dual-wire system creates a focal stress pattern to facilitate effective controlled plaque fracture at low-resolution pressure. In addition to its effective dilatation, Scoreflex has a low crossing profile and unbeatable trackability.



"Scoreflex has helped me prepare the vessel better prior to stent deployment," said Dato' Dr. Rosli Mohd Ali, head of the Cardiology Department, National Heart Institute, Kuala Lumpur, Malaysia. "It also has the potential to achieve good angiographic results when compared to using a regular balloon in treating bifurcation lesions and lesions affecting small vessels." ■